{"url_path":"/sec/smnrw/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1913577/0001193125-26-221896-index.html","accession_number":"0001193125-26-221896","cik":"0001913577","ticker":"SMNR","issuer_name":"Semnur Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1913577/0001193125-26-221896-index.html","primary_entity_key":"0001913577","primary_entity_name":"Semnur Pharmaceuticals, Inc."},"word_count":443,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nExhibit\n\nNumber\n\nDescription\n\nForm\n\nFile/Reg. No.\n\nExhibit\n\n \n\nFiling Date\n\n2.1#\n\n[Agreement and Plan of Merger, dated as of August 30, 2024, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc.](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001584541/000119312525178821/d887184ds4a.htm#toc887184_269)\n\nS-4\n\n333-283019\n\nAnnex A-1\n\nAugust 12, 2025\n\n \n\n \n\n \n\n \n\n2.2\n\n[Amendment No. 1 to Agreement and Plan of Merger, dated as of April 16, 2025, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc.](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001584541/000119312525178821/d887184ds4a.htm#toc887184_269a)\n\nS-4\n\n333-283019\n\nAnnex A-2\n\nApril 21, 2025\n\n \n\n \n\n \n\n \n\n2.3\n\n[Amendment No. 2 to Agreement and Plan of Merger, dated as of July 22, 2025, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc.](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001584541/000119312525178821/d887184ds4a.htm#toc887184_269b)\n\nS-4\n\n333-283019\n\nAnnex A-3\n\nJuly 23, 2025\n\n \n\n \n\n \n\n \n\n3.1\n\n[Restated Certificate of Incorporation of Semnur Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1913577/000119312525220455/d68253dex31.htm)\n\n8-K\n\n001-41351\n\n3.1\n\nSeptember 26, 2025\n\n \n\n \n\n \n\n \n\n3.2\n\n[Certificate of Designations of Semnur Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1913577/000119312525220455/d68253dex32.htm)\n\n8-K\n\n001-41351\n\n3.2\n\nSeptember 26, 2025\n\n \n\n \n\n \n\n \n\n3.3\n\n[Bylaws of Semnur Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1913577/000119312525220455/d68253dex33.htm)\n\n8-K\n\n001-41351\n\n3.3\n\nSeptember 26, 2025\n\n \n\n \n\n \n\n \n\n10.1\n\n[Separation Agreement, effective as of March 13, 2026, by and between Semnur Pharmaceuticals, Inc. and Jaisim Shah.](https://www.sec.gov/Archives/edgar/data/1913577/000119312526110816/smnr-ex10_1.htm)\n\n8-K\n\n001-41351\n\n \n\n10.1\n\nMarch 17, 2026\n\n \n\n \n\n \n\n \n\n31.1\n\n[Certification of Henry Ji,Ph.D., Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](smnr-ex31_1.htm).\n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n31.2\n\n[Certification of Stephen Ma, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](smnr-ex31_2.htm)\n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n32.1\n\n[Certification of Henry Ji, Ph.D., Principal Executive Officer, and Stephen Ma, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](smnr-ex32_1.htm)\n\nFurnished herewith\n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.\n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema with Embedded Linkbase Document.\n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n104\n\nCover Page (formatted as Inline XBRL and contained in Exhibit 101).\n\nFiled herewith\n\n \n\n \n\n \n\n* Indicates a management contract or compensatory plan.\n\n102\n\n \n\n# Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.\n\n103\n\n \n\nSIGNATURES\n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\n \n\nSemnur Pharmaceuticals, Inc.\n\n \n\n \n\n \n\n \n\nDate: May 13, 2026\n\n \n\nBy:\n\n/s/ Henry Ji, Ph.D.\n\n \n\n \n\n \n\nHenry Ji, Ph.D.\n\n \n\n \n\n \n\nChief Executive Officer and President\n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDate: May 13, 2026\n\n \n\nBy:\n\n/s/ Stephen Ma\n\n \n\n \n\n \n\nStephen Ma\n\n \n\n \n\n \n\nChief Financial Officer, Chief Operating Officer, Senior Vice President and Secretary\n(Principal Financial and Accounting Officer)\n\n \n\n104"}